| Drug Type CAR-NK | 
| Synonyms Anti-EGFR chimeric antigen receptor NK cell therapy - CytoImmune Therapeutics, CYT 501, CYT-101 + [2] | 
| Target | 
| Action modulators | 
| Mechanism EGFR modulators(Epidermal growth factor receptor erbB1 modulators) | 
| Therapeutic Areas | 
| Active Indication- | 
| Inactive Indication | 
| Originator Organization | 
| Active Organization- | 
| Inactive Organization | 
| License Organization | 
| Drug Highest PhasePendingPreclinical | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Glioblastoma | Preclinical | United States  | 03 Aug 2020 | 





